# Study to Evaluate ARD-101 in Adults With Obesity

> **NCT05121441** · PHASE2 · COMPLETED · sponsor: **Aardvark Therapeutics, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** ARD-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05121441
- **Lead sponsor:** Aardvark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2022-11-09
- **Final completion:** 2022-11-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121441, "Study to Evaluate ARD-101 in Adults With Obesity". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05121441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*